![]() |
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Fusion gene ID: 4276 |
FusionGeneSummary for BNIP3L_PMP22 |
![]() |
Fusion gene information | Fusion gene name: BNIP3L_PMP22 | Fusion gene ID: 4276 | Hgene | Tgene | Gene symbol | BNIP3L | PMP22 | Gene ID | 665 | 5376 |
Gene name | BCL2 interacting protein 3 like | peripheral myelin protein 22 | |
Synonyms | BNIP3a|NIX | CIDP|CMT1A|CMT1E|DSS|GAS-3|GAS3|HMSNIA|HNPP|Sp110 | |
Cytomap | 8p21.2 | 17p12 | |
Type of gene | protein-coding | protein-coding | |
Description | BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-likeBCL2/adenovirus E1B 19 kDa protein-interacting protein 3ABCL2/adenovirus E1B 19-kd protein-interacting protein 3aBCL2/adenovirus E1B 19kDa interacting protein 3 likeNIP-3-like protein XNIP3 | peripheral myelin protein 22growth arrest-specific protein 3peripheral myelin protein 22 kDa | |
Modification date | 20180523 | 20180523 | |
UniProtAcc | O60238 | Q01453 | |
Ensembl transtripts involved in fusion gene | ENST00000380629, ENST00000523515, ENST00000520409, ENST00000518611, ENST00000521254, | ENST00000395938, ENST00000312280, ENST00000494511, ENST00000395936, ENST00000426385, | |
Fusion gene scores | * DoF score | 3 X 3 X 1=9 | 5 X 5 X 2=50 |
# samples | 4 | 5 | |
** MAII score | log2(4/9*10)=2.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(5/50*10)=0 | |
Context | PubMed: BNIP3L [Title/Abstract] AND PMP22 [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | BNIP3L | GO:0043065 | positive regulation of apoptotic process | 9973195 |
Hgene | BNIP3L | GO:0043066 | negative regulation of apoptotic process | 10381623 |
Hgene | BNIP3L | GO:0051607 | defense response to virus | 9973195 |
Tgene | PMP22 | GO:0008219 | cell death | 12107182 |
Tgene | PMP22 | GO:0032060 | bleb assembly | 12107182 |
![]() (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChiTaRS3.1 | AI081942 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
3UTR-3UTR | ENST00000380629 | ENST00000395938 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
3UTR-3UTR | ENST00000380629 | ENST00000312280 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
3UTR-3UTR | ENST00000380629 | ENST00000494511 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
3UTR-3UTR | ENST00000380629 | ENST00000395936 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
3UTR-intron | ENST00000380629 | ENST00000426385 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-3UTR | ENST00000523515 | ENST00000395938 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-3UTR | ENST00000523515 | ENST00000312280 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-3UTR | ENST00000523515 | ENST00000494511 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-3UTR | ENST00000523515 | ENST00000395936 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-intron | ENST00000523515 | ENST00000426385 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-3UTR | ENST00000520409 | ENST00000395938 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-3UTR | ENST00000520409 | ENST00000312280 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-3UTR | ENST00000520409 | ENST00000494511 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-3UTR | ENST00000520409 | ENST00000395936 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-intron | ENST00000520409 | ENST00000426385 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
3UTR-3UTR | ENST00000518611 | ENST00000395938 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
3UTR-3UTR | ENST00000518611 | ENST00000312280 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
3UTR-3UTR | ENST00000518611 | ENST00000494511 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
3UTR-3UTR | ENST00000518611 | ENST00000395936 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
3UTR-intron | ENST00000518611 | ENST00000426385 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-3UTR | ENST00000521254 | ENST00000395938 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-3UTR | ENST00000521254 | ENST00000312280 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-3UTR | ENST00000521254 | ENST00000494511 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-3UTR | ENST00000521254 | ENST00000395936 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
intron-intron | ENST00000521254 | ENST00000426385 | BNIP3L | chr8 | 26268430 | - | PMP22 | chr17 | 15134169 | + |
Top |
FusionProtFeatures for BNIP3L_PMP22 |
![]() |
Hgene | Tgene |
BNIP3L | PMP22 |
Induces apoptosis. Interacts with viral and cellularanti-apoptosis proteins. Can overcome the suppressors BCL-2 andBCL-XL, although high levels of BCL-XL expression will inhibitapoptosis. Inhibits apoptosis induced by BNIP3. Involved inmitochondrial quality control via its interaction withSPATA18/MIEAP: in response to mitochondrial damage, participatesin mitochondrial protein catabolic process (also named MALM)leading to the degradation of damaged proteins insidemitochondria. The physical interaction of SPATA18/MIEAP, BNIP3 andBNIP3L/NIX at the mitochondrial outer membrane regulates theopening of a pore in the mitochondrial double membrane in order tomediate the translocation of lysosomal proteins from the cytoplasmto the mitochondrial matrix. May function as a tumor suppressor.{ECO:0000269|PubMed:10381623, ECO:0000269|PubMed:21264228}. | Might be involved in growth regulation, and inmyelinization in the peripheral nervous system. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for BNIP3L_PMP22 |
![]() (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for BNIP3L_PMP22 |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for BNIP3L_PMP22 |
![]() (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for BNIP3L_PMP22 |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | PMP22 | C0011195 | Dejerine-Sottas Disease (disorder) | 18 | ORPHANET;UNIPROT |
Tgene | PMP22 | C0270911 | Charcot-Marie-Tooth Disease, Type Ia (disorder) | 14 | ORPHANET;UNIPROT |
Tgene | PMP22 | C0007959 | Charcot-Marie-Tooth Disease | 3 | CTD_human |
Tgene | PMP22 | C0393814 | Hereditary liability to pressure palsies | 3 | CTD_human;ORPHANET;UNIPROT |
Tgene | PMP22 | C3495591 | Charcot-Marie-Tooth Disease, Demyelinating, Type 1e | 3 | CTD_human;UNIPROT |
Tgene | PMP22 | C0031117 | Peripheral Neuropathy | 2 | CTD_human |
Tgene | PMP22 | C0008073 | Developmental Disabilities | 1 | CTD_human |
Tgene | PMP22 | C0011303 | Demyelinating Diseases | 1 | CTD_human |
Tgene | PMP22 | C0014550 | Epilepsies, Myoclonic | 1 | CTD_human |
Tgene | PMP22 | C0027888 | Hereditary Motor and Sensory Neuropathies | 1 | CTD_human |
Tgene | PMP22 | C0030554 | Paresthesia | 1 | CTD_human;HPO |
Tgene | PMP22 | C0034372 | Quadriplegia | 1 | CTD_human |
Tgene | PMP22 | C0034933 | Reflex, Abnormal | 1 | CTD_human |
Tgene | PMP22 | C0151786 | Muscle Weakness | 1 | CTD_human;HPO |